differentiation syndrome

Etiology: - enasidenib (Idhifa) Clinical manifestations: - fever - dyspnea, acute respiratory distress - pulmonary infiltrates - pleural effusion - pericardial effusion - peripheral edema - liver failure - acute renal failure - multi-organ dysfunction Complications: - can be fatal if not treated Management: - glucocorticoids with close monitoring until symptoms abare

General

drug adverse effect(s) of syndrome

References

FDA News Release. August 1, 2017 FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm569421.htm